2024
Estimated Population-Level Impact of Pneumococcal Conjugate Vaccines Against All-Cause Pneumonia Mortality Among Unvaccinated in 5 Latin American Countries
Prunas O, Shioda K, Toscano C, Bastias M, Valenzuela-Bravo M, Tito J, Warren J, Weinberger D, de Oliveira L. Estimated Population-Level Impact of Pneumococcal Conjugate Vaccines Against All-Cause Pneumonia Mortality Among Unvaccinated in 5 Latin American Countries. The Journal Of Infectious Diseases 2024, jiae144. PMID: 38502711, DOI: 10.1093/infdis/jiae144.Peer-Reviewed Original ResearchAll-cause pneumoniaPneumonia deathsPneumonia mortalityAge groupsPneumococcal conjugate vaccineProportion of IPD casesInvasive pneumococcal diseaseMulti-country studyIPD casesOlder age groupsPopulation-level impactMortality dataYears of ageInvasive pneumococcal disease casesConjugate vaccinePneumococcal conjugate vaccine introductionEffect of pneumococcal conjugate vaccinesTemporal trendsImpact of pneumococcal conjugate vaccinesUnvaccinated age groupsMortalityEvaluate changesPost-vaccination periodVaccine serotypesNo significant changes
2023
Incorporating Data from Multiple Endpoints in the Analysis of Clinical Trials: Example from RSV Vaccines
Prunas O, Willemsen J, Bont L, Pitzer V, Warren J, Weinberger D. Incorporating Data from Multiple Endpoints in the Analysis of Clinical Trials: Example from RSV Vaccines. Epidemiology 2023, 35: 103-112. PMID: 37793120, DOI: 10.1097/ede.0000000000001680.Peer-Reviewed Original ResearchIncorporating Efficacy Data from Initial Trials Into Subsequent Evaluations: Application to Vaccines Against Respiratory Syncytial Virus
Warren J, Sundaram M, Pitzer V, Omer S, Weinberger D. Incorporating Efficacy Data from Initial Trials Into Subsequent Evaluations: Application to Vaccines Against Respiratory Syncytial Virus. Epidemiology 2023, 35: 130-136. PMID: 37963353, PMCID: PMC10842163, DOI: 10.1097/ede.0000000000001690.Peer-Reviewed Original Research
2022
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
Prunas O, Warren JL, Crawford FW, Gazit S, Patalon T, Weinberger DM, Pitzer VE. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. Science 2022, 375: eabl4292. PMID: 35084937, PMCID: PMC9261115, DOI: 10.1126/science.abl4292.Peer-Reviewed Original ResearchConceptsVaccine effectivenessSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Effectiveness of vaccinesEffectiveness of vaccinationTotal vaccine effectivenessSARS-CoV-2Household contactsSecond doseCoronavirus 2Household transmissionDelta variantDay 10VaccinationBNT162b2COVID-19InfectionChain binomial modelVaccineDoseImmunity